Edwards Lifesciences Corp (EW) VP Sells $1,291,755.44 in Stock

Edwards Lifesciences Corp (NYSE:EW) VP Larry L. Wood sold 6,716 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $192.34, for a total transaction of $1,291,755.44. Following the completion of the transaction, the vice president now directly owns 122,495 shares of the company’s stock, valued at approximately $23,560,688.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of NYSE EW traded down $1.10 during trading on Friday, hitting $176.12. The company had a trading volume of 1,265,412 shares, compared to its average volume of 1,340,253. Edwards Lifesciences Corp has a fifty-two week low of $127.29 and a fifty-two week high of $197.86. The firm has a market cap of $37.65 billion, a price-to-earnings ratio of 37.47, a price-to-earnings-growth ratio of 2.35 and a beta of 0.91. The company has a quick ratio of 1.92, a current ratio of 2.61 and a debt-to-equity ratio of 0.19.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.09. The firm had revenue of $993.00 million for the quarter, compared to analyst estimates of $989.87 million. Edwards Lifesciences had a net margin of 20.03% and a return on equity of 31.71%. Edwards Lifesciences’s quarterly revenue was up 11.0% on a year-over-year basis. During the same period in the previous year, the business posted $1.22 earnings per share. Equities research analysts anticipate that Edwards Lifesciences Corp will post 5.22 EPS for the current fiscal year.

Several research analysts recently issued reports on the stock. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their target price for the stock from $180.00 to $190.00 in a report on Friday, January 18th. Citigroup raised their target price on shares of Edwards Lifesciences from $118.00 to $119.00 and gave the stock a “sell” rating in a report on Wednesday, January 2nd. Raymond James reduced their target price on shares of Edwards Lifesciences from $210.00 to $200.00 and set an “outperform” rating for the company in a report on Wednesday. Morgan Stanley raised their target price on shares of Edwards Lifesciences from $180.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, March 18th. Finally, Barclays raised their target price on shares of Edwards Lifesciences from $150.00 to $160.00 and gave the stock an “underweight” rating in a report on Monday, March 25th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $187.19.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. AMP Capital Investors Ltd raised its stake in Edwards Lifesciences by 22.3% during the third quarter. AMP Capital Investors Ltd now owns 91,546 shares of the medical research company’s stock worth $15,762,000 after purchasing an additional 16,701 shares during the period. Standard Life Aberdeen plc raised its stake in Edwards Lifesciences by 8.7% during the third quarter. Standard Life Aberdeen plc now owns 81,459 shares of the medical research company’s stock worth $14,184,000 after purchasing an additional 6,529 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Edwards Lifesciences by 65.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 19,768 shares of the medical research company’s stock worth $3,428,000 after purchasing an additional 7,792 shares during the period. GAM Holding AG raised its stake in Edwards Lifesciences by 3.3% during the third quarter. GAM Holding AG now owns 25,506 shares of the medical research company’s stock worth $4,441,000 after purchasing an additional 806 shares during the period. Finally, Bridgewater Associates LP purchased a new position in Edwards Lifesciences during the third quarter worth about $1,670,000. Hedge funds and other institutional investors own 84.89% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/26/insider-selling-edwards-lifesciences-corp-ew-vp-sells-1291755-44-in-stock.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Further Reading: How Important is Technical Analysis of Stocks

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.